Bacterial product meant to treat inflammatory bowel diseases. The microbiome pharmaceutical candidate, VE202, is a mix of bacteria from the Clostridia subspecies that could be a treatment for Crohn's disease and ulcerative colitis. It will will help either replenish or rejuvenate a type of immune cell called regulatory T-cells, which help the body cool off inflammation.